戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 rictions for people co-infected with HIV and hepatitis C virus.
2  compounds showed antiviral activity against hepatitis C virus.
3 be avoided in black patients with genotype 1 hepatitis C virus.
4 a performed well in patients with cACLD with hepatitis C virus and alcoholic and nonalcoholic steatoh
5    We demonstrate that, in sharp contrast to hepatitis C virus and human immunodeficiency virus patie
6            Although the related flaviviruses hepatitis C virus and human pegivirus (formerly named GB
7                            Understanding how hepatitis C virus and other flaviviruses interact with t
8 ople have been estimated to be infected with hepatitis C virus, and many more are at risk for infecti
9 a from patients with AIH, hepatitis B virus, hepatitis C virus, and nonalcoholic steatohepatitis.
10             BACKGROUND & AIMS: Patients with hepatitis C virus-associated cirrhosis and clinical sign
11 enter prospective study of 226 patients with hepatitis C virus-associated cirrhosis and CSPH who had
12 lticenter prospective study of patients with hepatitis C virus-associated cirrhosis, an SVR to all-or
13 a4 that might explain its negative effect on hepatitis C virus clearance.
14 r 24 weeks in 9 human immunodeficiency virus/hepatitis C virus-coinfected patients who relapsed after
15 or ultrasensitive and selective detection of hepatitis C virus core antigen (HCV) have been investiga
16                                  Testing for hepatitis C virus core antigen (HCVcAg) is a potential a
17 substratum to load antibody for detection of hepatitis C virus core antigen.
18 SV) 1 and 2, human immunodeficiency virus 1, hepatitis C virus, enterovirus 70, and variant Creutzfel
19   This issue provides a clinical overview of hepatitis C virus, focusing on transmission, prevention,
20 available North American sequences from five hepatitis C virus genes (E1, E2, NS2, NS4B, NS5B), with
21 MC647055/ritonavir + JNJ-56914845 in chronic hepatitis C virus genotype (GT)1-infected treatment-naiv
22 confidence interval, 86%-100%) patients with hepatitis C virus genotype 1 infection, 13 of 14 (93%; 9
23  6 weeks or less among patients with chronic hepatitis C virus genotype 1 infection.
24 rated and effective, particularly those with hepatitis C virus genotype 1 or 2 infection.
25 eened 45 316 publicly available sequences of hepatitis C virus genotype 1a for location and genotype,
26 highly effective in adolescents with chronic hepatitis C virus genotype 2 or 3 infection.
27 and ribavirin in adolescents aged 12-17 with hepatitis C virus genotype 2 or 3.
28                                Patients with hepatitis C virus genotype 3 infection with prior treatm
29 caprevir/pibrentasvir (G/P) in patients with hepatitis C virus genotype 3 infection with prior treatm
30                      Chronic infections with hepatitis C virus (HCV) and HIV are highly prevalent in
31                     Persons co-infected with hepatitis C virus (HCV) and HIV.
32                    Patients co-infected with hepatitis C virus (HCV) and human immunodeficiency virus
33 steatosis (HS) is common in individuals with hepatitis C virus (HCV) and human immunodeficiency virus
34   Patients who are chronically infected with hepatitis C virus (HCV) and who do not have a sustained
35  [BPA], and patient solicitation), evaluated hepatitis C virus (HCV) antibody testing, diagnosis, and
36 afety and efficacy in treating patients with hepatitis C virus (HCV) awaiting liver transplant (LT).
37                                              Hepatitis C virus (HCV) causes chronic infections in at
38                                              Hepatitis C virus (HCV) causes mixed cryoglobulinemia (M
39 urrent standard of care for the treatment of hepatitis C virus (HCV) consists of interferon-free dire
40 lines were genetically engineered to display Hepatitis C virus (HCV) core antigen linked to gold bind
41                                              Hepatitis C virus (HCV) cure rates have been similar in
42         In this report, we demonstrated that hepatitis C virus (HCV) depleted TRAF6 from its host cel
43                                              Hepatitis C virus (HCV) displays a restricted host speci
44 st immune system to the efficacy of new anti-hepatitis C virus (HCV) drugs is unclear.
45  recently been identified as an inhibitor of hepatitis C virus (HCV) entry.
46  we longitudinally sampled and sequenced the hepatitis C virus (HCV) envelope genome region (1,680 nu
47 ey population affected by the global HIV and hepatitis C virus (HCV) epidemics.
48        The Asia-Pacific region has disparate hepatitis C virus (HCV) epidemiology, with prevalence ra
49                                              Hepatitis C virus (HCV) establishes persistent infection
50                                              Hepatitis C virus (HCV) exists as a lipoprotein-virus hy
51 cessary; however, PEP is not recommended for hepatitis C virus (HCV) exposures.
52           Patients chronically infected with hepatitis C virus (HCV) frequently develop mixed cryoglo
53 S5A, which is involved in replication of the hepatitis C virus (HCV) genome, presumably via membranou
54 r + DSV) +/- ribavirin (RBV) is approved for hepatitis C virus (HCV) genotype 1 (GT1) treatment in HI
55 n the United States for treatment of chronic hepatitis C virus (HCV) genotype 1 and 4 infections, as
56         The optimal retreatment strategy for hepatitis C virus (HCV) genotype 1-infected patients who
57     BACKGROUND & AIMS: Patients with chronic hepatitis C virus (HCV) genotype 2 have high rates of re
58                                              Hepatitis C virus (HCV) genotype 4 infection is most com
59 pproved treatment regimens for patients with hepatitis C virus (HCV) genotypes (GTs) 2 and 3 contain
60 ive samples, linearity, and performance with hepatitis C virus (HCV) genotypes were evaluated.
61                             Current national hepatitis C virus (HCV) guidelines do not recommend the
62                          B-cell infection by hepatitis C virus (HCV) has been a controversial topic.
63                                              Hepatitis C virus (HCV) has been shown to induce autopha
64                                              Hepatitis C virus (HCV) has dominated the field of hepat
65 atients chronically infected with genotype 3 hepatitis C virus (HCV) have faster disease progression
66 is study examined the interactions among the hepatitis C virus (HCV) helicase and RLR helicases in li
67                         miR-122, a pro-viral hepatitis C virus (HCV) host factor, binds and recruits
68 changes that occur upon prolonged passage of hepatitis C virus (HCV) in human hepatoma cells in an ex
69 tly-acting antivirals has been advocated for Hepatitis C Virus (HCV) in people who inject drugs (PWID
70  dynamics, and phenotypic diversification of hepatitis C virus (HCV) in the course of 200 passages in
71 We determined temporal trends (1985-2011) in hepatitis C virus (HCV) incidence and associated behavio
72                                              Hepatitis C virus (HCV) infection affects over 130 milli
73 ing antiviral agents that can cure a chronic hepatitis C virus (HCV) infection after 8-12 weeks of da
74  recommended regimens to treat patients with hepatitis C virus (HCV) infection after liver transplant
75                         Treatment of chronic hepatitis C virus (HCV) infection after renal allograft
76 known of an epidemic of sexually transmitted hepatitis C virus (HCV) infection among human immunodefi
77  response (SVR) on outcomes of patients with hepatitis C virus (HCV) infection and compensated cirrho
78 lecaprevir and pibrentasvir in patients with hepatitis C virus (HCV) infection and compensated cirrho
79                      The association between hepatitis C virus (HCV) infection and end-stage renal di
80 egimen for 12 weeks in patients with chronic hepatitis C virus (HCV) infection and stage 4-5 chronic
81 ociations between hepatitis B virus (HBV) or hepatitis C virus (HCV) infection and the development of
82 AIT cells in livers of patients with chronic hepatitis C virus (HCV) infection and their fate after a
83                                  Outcomes of hepatitis C virus (HCV) infection and treatment depend o
84 pment of drugs targeting the early stages of Hepatitis C virus (HCV) infection are hampered by the la
85 tive studies of the outcomes associated with hepatitis C virus (HCV) infection are rare and critical
86 have demonstrated that patients with chronic hepatitis C virus (HCV) infection associated HCC survive
87 nbiased genome-to-genome analysis in chronic hepatitis C virus (HCV) infection confirms the innate an
88                              Whether chronic hepatitis C virus (HCV) infection decreases humoral and
89  with persistent and spontaneously resolving hepatitis C virus (HCV) infection during the acute phase
90                                              Hepatitis C virus (HCV) infection has been associated wi
91                        In the United States, hepatitis C virus (HCV) infection has increased among yo
92    Direct-acting antiviral (DAA) therapy for hepatitis C virus (HCV) infection has resulted in high r
93 acting antiviral (DAA) therapies for chronic hepatitis C virus (HCV) infection have demonstrated high
94     BACKGROUND & AIMS: Patients with chronic hepatitis C virus (HCV) infection have high rates of sus
95 of interferon and ribavirin to treat chronic hepatitis C virus (HCV) infection in kidney transplant r
96 of interferon and ribavirin to treat chronic hepatitis C virus (HCV) infection in kidney transplant r
97 ffective, and pan-genotypic regimen to treat hepatitis C virus (HCV) infection in patients coinfected
98 ng antiviral (DAA) medications, treatment of hepatitis C virus (HCV) infection in renal transplant re
99 asvir-sofosbuvir is effective at eradicating hepatitis C virus (HCV) infection in the general populat
100      In a previous study, we have shown that hepatitis C virus (HCV) infection induces epithelial-mes
101                                              Hepatitis C virus (HCV) infection is a common risk facto
102                   BACKGROUND & AIMS: Chronic hepatitis C virus (HCV) infection is a major burden on i
103                                              Hepatitis C virus (HCV) infection is a major cause of li
104                                              Hepatitis C virus (HCV) infection is a major risk factor
105                                      Chronic hepatitis C virus (HCV) infection is associated with imp
106        Direct-acting antiviral treatment for hepatitis C virus (HCV) infection is costly and does not
107  efficacy of antiviral treatment for chronic hepatitis C virus (HCV) infection is determined by measu
108                                      Chronic hepatitis C virus (HCV) infection is more prevalent amon
109                                              Hepatitis C virus (HCV) infection is prevalent in the re
110                                              Hepatitis C virus (HCV) infection is the most common chr
111                      A vaccine that prevents hepatitis C virus (HCV) infection is urgently needed to
112                 The mechanism of how chronic hepatitis C virus (HCV) infection leads to such a high r
113  immunodeficiency virus (HIV) and/or chronic hepatitis C virus (HCV) infection may be prescribed stat
114 s stage influences the CHF risk or if HIV or hepatitis C virus (HCV) infection modifies this associat
115  Whether chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) infection promote NHL in HIV-inf
116  The immuno-pathogenic mechanisms of chronic hepatitis C virus (HCV) infection remain to be elucidate
117 lines now recommend that patients with acute hepatitis C virus (HCV) infection should be treated with
118 e the relationships of hepatitis B (HBV) and hepatitis C virus (HCV) infection to age-related catarac
119          The predisposition of patients with Hepatitis C virus (HCV) infection to hepatocellular carc
120 atocellular carcinoma (HCC) in patients with hepatitis C virus (HCV) infection treated with direct-ac
121                          Historically, acute hepatitis C virus (HCV) infection was treated with short
122                                  People with hepatitis C virus (HCV) infection who have failed treatm
123                      Treatment of genotype 1 hepatitis C virus (HCV) infection with combination direc
124 lete regimen for adult patients with chronic hepatitis C virus (HCV) infection without cirrhosis or w
125 ivirals (DAAs) effectively eradicate chronic hepatitis C virus (HCV) infection, although HCV genotype
126          Fibrosis is associated with chronic hepatitis C virus (HCV) infection, although the mechanis
127 ins are detected in 40%-60% of patients with hepatitis C virus (HCV) infection, and overt cryoglobuli
128 e the availability of curative treatment for hepatitis C virus (HCV) infection, because of cost, trea
129 ptor proteins AP1 and AP2, are essential for hepatitis C virus (HCV) infection, but the underlying me
130 h cure rate in treated patients with chronic hepatitis C virus (HCV) infection, but this still leaves
131                  For an efficient control of hepatitis C virus (HCV) infection, cytotoxic T cells (CT
132 ent of more effective drugs for treatment of hepatitis C virus (HCV) infection, there has been an inc
133  central role in the pathogenesis of chronic hepatitis C virus (HCV) infection.
134 esent the standard of care for patients with hepatitis C virus (HCV) infection.
135 agents (DAAs) are used increasingly to treat hepatitis C virus (HCV) infection.
136 have been approved for children with chronic hepatitis C virus (HCV) infection.
137 eradication to >90% in patients with chronic hepatitis C virus (HCV) infection.
138 protease inhibitor GS-9857, in patients with hepatitis C virus (HCV) infection.
139  patients with inherited blood disorders and hepatitis C virus (HCV) infection.
140                                 Outbreaks of hepatitis C virus (HCV) infections are associated with u
141 artments (EDs) seem to be able to detect new hepatitis C virus (HCV) infections at a high rate, but i
142                    All patients with chronic hepatitis C virus (HCV) infections can and should be tre
143                                              Hepatitis C virus (HCV) infects 200 million people globa
144                                              Hepatitis C virus (HCV) is a global health concern that
145                                              Hepatitis C virus (HCV) is a single-stranded positive-se
146                                              Hepatitis C virus (HCV) is a unique enveloped virus that
147                            The p7 protein of hepatitis C virus (HCV) is an intracellular ion channel
148                        Occult infection with hepatitis C virus (HCV) is defined as the presence of th
149 itious targets for global control of HIV and hepatitis C virus (HCV) is low levels of awareness of in
150                    Viral load monitoring for hepatitis C virus (HCV) is necessary to diagnose infecti
151                                              Hepatitis C virus (HCV) is one of the leading causes of
152                       Chronic infection with hepatitis C virus (HCV) is one of the main causes of hep
153                     Vertical transmission of hepatitis C virus (HCV) is the most common route of pedi
154                                              Hepatitis C virus (HCV) is unique among RNA viruses in i
155 ontributed to increased understanding of the hepatitis C virus (HCV) life cycle.
156 formed by glycoproteins E1 and E2 within the hepatitis C virus (HCV) lipid envelope is a potential va
157                                              Hepatitis C virus (HCV) nonstructural protein 5A (NS5A)
158 nt pan-genotype and macrocyclic inhibitor of hepatitis C virus (HCV) NS3/4A protease and was develope
159         BACKGROUND & AIMS: Inhibitors of the hepatitis C virus (HCV) NS5A protein are a key component
160                                          The hepatitis C virus (HCV) NS5B replicase is a prime target
161                                              Hepatitis C virus (HCV) often causes persistent infectio
162 enib with alternative therapies according to hepatitis C virus (HCV) or hepatitis B virus (HBV) statu
163 rotein synthesis to directly incorporate the hepatitis C virus (HCV) p7 protein into supported lipid
164 s an urgent need for a vaccine to combat the hepatitis C virus (HCV) pandemic, and induction of broad
165 rd-of-care treatment of chronically infected hepatitis C virus (HCV) patients involves direct-acting
166  inhibitors, particularly those of HIV-1 and hepatitis C virus (HCV) protease, revealed a plethora of
167                                              Hepatitis C virus (HCV) reactivation in patients receivi
168 to assess human immunodeficiency virus (HIV)/hepatitis C virus (HCV) real-world treatment outcomes.
169 pite recent advances in therapeutic options, hepatitis C virus (HCV) remains a severe global disease
170                                              Hepatitis C virus (HCV) remains the leading indication f
171 , exhibit potent inhibitory activity against hepatitis C virus (HCV) replication in genotype 1b Con 1
172 croRNAs (miRNAs) have been shown to regulate hepatitis C virus (HCV) replication, yet a systematic in
173      miR-122 is an important host factor for hepatitis C virus (HCV) replication.
174                                  Reliance on hepatitis C virus (HCV) replicon systems and protein-bas
175                                              Hepatitis C virus (HCV) requires multiple receptors for
176 polymerase that catalyzes replication of the hepatitis C virus (HCV) RNA genome and therefore is cent
177     The affordable and reliable detection of Hepatitis C Virus (HCV) RNA is a cornerstone in the mana
178                                Point-of-care hepatitis C virus (HCV) RNA testing offers an advantage
179                                     Targeted hepatitis C virus (HCV) screening is recommended.
180  an electronic health record-based prompt on hepatitis C virus (HCV) screening rates in baby boomers
181 ntive Services Task Force recommend one-time hepatitis C virus (HCV) testing for persons born during
182 ntrol and Prevention (CDC) recommends 1-time hepatitis C virus (HCV) testing in the 1945-1965 birth c
183                             Highly effective hepatitis C virus (HCV) therapies have spurred a scale-u
184                          There is a need for hepatitis C virus (HCV) therapies with excellent efficac
185                                          New hepatitis C virus (HCV) therapies with pan-genotypic eff
186                        Rapid improvements in hepatitis C virus (HCV) therapy have led to the approval
187 out substitutions that mediate resistance of hepatitis C virus (HCV) to direct-acting antivirals (DAA
188 ral direct-acting antivirals has altered the hepatitis C virus (HCV) treatment paradigm for both pre-
189        Cost-effectiveness analyses (CEAs) of hepatitis C virus (HCV) treatment strategies have become
190 ivirals (DAAs) have changed the landscape of hepatitis C virus (HCV) treatment, but chronic hepatitis
191                               Eradication of hepatitis C virus (HCV) using direct-acting agents (DAA)
192 e models has been an obstacle for developing hepatitis C virus (HCV) vaccines and affordable antivira
193                                 Clearance of hepatitis C virus (HCV) via antiviral treatment changes
194                           The association of hepatitis C virus (HCV) with non-Hodgkin's lymphoma (NHL
195                                              Hepatitis C virus (HCV)(+) donors represent an effective
196 ect drugs (PWID); and the prevalence of HIV, hepatitis C virus (HCV), and hepatitis B virus (HBV) amo
197 ected by human immunodeficiency virus (HIV), hepatitis C virus (HCV), and hepatitis B virus (HBV).
198  for detection of cirrhosis in patients with hepatitis C virus (HCV), hepatitis B virus (HBV), NAFLD,
199 th decompensated cirrhosis (DC) secondary to hepatitis C virus (HCV), is associated with improved hep
200 RNA (+RNA) viruses including human pathogens hepatitis C virus (HCV), Severe acute respiratory syndro
201  burden posed by hepatitis B virus (HBV) and hepatitis C virus (HCV), to learn from each other's expe
202  with human immunodeficiency virus (HIV) and hepatitis C virus (HCV), we assessed fibrosis progressio
203 cohort of human immunodeficiency virus (HIV)/hepatitis C virus (HCV)-coinfected patients treated with
204 was cloned from T cells that expanded when a hepatitis C virus (HCV)-infected HLA-A2(-) individual re
205 A) is the nation's largest care provider for hepatitis C virus (HCV)-infected patients and is uniquel
206 k of chronic kidney disease (CKD) in chronic hepatitis C virus (HCV)-infected patients and the incide
207                                              Hepatitis C virus (HCV)-infected patients with chronic k
208 d high efficacy, safety, and tolerability in hepatitis C virus (HCV)-infected patients.
209       We prospectively evaluated 251 chronic hepatitis C virus (HCV)-infected subjects (31% human imm
210                                       Within hepatitis C virus (HCV)-like IRES elements, the sub-doma
211                                              Hepatitis C virus (HCV)-mediated chronic liver disease i
212                                  Identifying hepatitis C virus (HCV)-positive persons at high risk of
213 k of acute myocardial infarction (AMI) among hepatitis C virus (HCV)-positive versus HCV-negative per
214  (NAFLD-HCC) and to compare them to those of hepatitis C virus (HCV)-related HCC.
215      Guidelines recommend that patients with hepatitis C virus (HCV)-related liver disease be treated
216                     The antiviral effects of hepatitis C virus (HCV)-specific CD8 T cells have been s
217 on individuals are chronically infected with hepatitis C virus (HCV).
218 oRNA-122 is an important host factor for the hepatitis C virus (HCV).
219 cy virus (HIV), hepatitis B virus (HBV), and hepatitis C virus (HCV).
220 1 million people worldwide are infected with hepatitis C virus (HCV).
221  is required for infection of hepatocytes by hepatitis C virus (HCV).
222 s) after infection with cell culture-derived hepatitis C virus (HCV).
223  is required for infection of hepatocytes by hepatitis C virus (HCV).
224 IM-1 is important for efficient infection by hepatitis C virus (HCV).
225 l survival benefit for persons infected with hepatitis C virus (HCV).
226  mortality in patients with cirrhosis due to hepatitis C virus (HCV).
227 related to either hepatitis B virus (HBV) or hepatitis C virus (HCV).
228 n of antiretroviral therapy in patients with hepatitis C virus (HCV)/HIV-1 coinfection.
229 ly observed in individuals infected with the hepatitis C virus (HCV); however, the underlying molecul
230                                              Hepatitis C viruses (HCV) encode a helicase enzyme that
231                   A recombinant strain HCV1 (hepatitis C virus [HCV] genotype 1a) gpE1/gpE2 (E1E2) va
232 igh rates of sustained virological response (hepatitis C virus [HCV] RNA <15 IU/mL) at post-treatment
233  serostatus (+ or -: hepatitis B core [HBc], hepatitis C virus [HCV], Epstein-Barr virus [EBV], or cy
234 st a wide variety of viruses, including HIV, hepatitis C virus, hepatitis B virus, enterovirus 71, in
235 as well as profound antiviral effect against hepatitis C virus, human rhinovirus, and coxsackievirus
236 or without ribavirin as treatment of chronic hepatitis C virus in solid organ transplant recipients a
237 AA) therapies are effective in patients with hepatitis C virus-induced cryoglobulinemia vasculitis (H
238 hepatitis B virus (HBV) has been reported in hepatitis C virus-infected individuals receiving direct-
239                         We identified 21,095 hepatitis C virus-infected patients (11,029 [52%] white,
240  HIV-negative patients with cancer (n = 53), hepatitis C virus-infected patients (n = 17), and health
241  the PITER cohort (representative of Italian hepatitis C virus-infected patients in care).
242 ir (LDV/SOF) can be considered in genotype 1 hepatitis C virus-infected patients who are treatment-na
243  treatment policies in a real-life cohort of hepatitis C virus-infected policy 1, "universal," treat
244 his retrospective evaluation included 62,290 hepatitis C virus-infected veterans completing oral DAA
245 n (54.1%, P = 0.001), had lower incidence of hepatitis C virus infection (4.9%, P = 0.001) and longer
246 old-especially those born in the peak era of hepatitis C virus infection and among whites/Caucasians.
247  preclinical candidates for the treatment of hepatitis C virus infection and as probes to study hepat
248 called mixed cryoglobulinemia and is seen in hepatitis C virus infection and systemic diseases such a
249                        Children with chronic hepatitis C virus infection have limited treatment optio
250 antiviral drugs for the treatment of chronic hepatitis C virus infection have reduced mortality and t
251 s after DAA therapy in patients with chronic hepatitis C virus infection in the context of the immune
252                                      Chronic hepatitis C virus infection is associated with significa
253                                      Chronic hepatitis C virus infection is well-recognized as a comm
254  report a case series of three patients with hepatitis C virus infection who all presented with sever
255 djusted for age, race or ethnicity, smoking, hepatitis C virus infection, alcohol use disorders, drug
256  and well tolerated in patients with chronic hepatitis C virus infection, including those with compen
257 ) to interferon-based treatments for chronic hepatitis C virus infection, whereas Asian race was asso
258  New Zealand of 197 patients with genotype 1 hepatitis C virus infection, with or without compensated
259 revolutionized care of patients with chronic hepatitis C virus infection.
260 iral cytokine, are also less likely to clear hepatitis C virus infection.
261 us infection; 29.1% (95% CI: 23.6-34.5%) for hepatitis C virus infection; 33.9% (95% CI: 24.3-43.5%)
262 through the control of hepatitis B virus and hepatitis C virus infections by vaccination and treatmen
263 epatitis, especially chronic hepatitis B and hepatitis C virus infections.
264 ture-based design of HCV vaccines.IMPORTANCE Hepatitis C virus is a leading cause of liver disease an
265 lization of replication complexes.IMPORTANCE Hepatitis C virus is an important human pathogen.
266 stimulation during persistent infection with hepatitis C virus is associated with continuous activati
267                                              Hepatitis C virus is capable of establishing a lifelong
268 listed women differed in age (58 vs 57), non-hepatitis C virus listing diagnoses (69% vs 56%), hepati
269  29382 young persons currently infected with hepatitis C virus lived >10 miles from a syringe service
270 itis C virus-positive (50.9-57.9 years) than hepatitis C virus-negative (51.3-54.3 years) registrants
271                                           In hepatitis C virus-negative patients, aging trends were d
272 avage of four novel substrate motifs for the hepatitis C virus NS3/4 protease using an in vivo assay.
273           The mechanisms by which infectious hepatitis C virus particles are assembled and released f
274 tis C virus infection and as probes to study hepatitis C virus pathogenesis and host-virus interactio
275 We conducted a retrospective cohort study of hepatitis C virus patients who were treated with DAA in
276 ood and tissue donors, persons infected with hepatitis C virus, persons with elevated alanine aminotr
277 s to those of the initiation complex for the hepatitis C virus polymerase.
278 th cold ischemic time >12 hours, livers from hepatitis C virus positive donors, livers from donation
279 5.7 years, with a more prominent increase in hepatitis C virus-positive (50.9-57.9 years) than hepati
280 ed from 2002 to 2014, driven by aging of the hepatitis C virus-positive cohort and increased prevalen
281                  In particular, how and when hepatitis C virus reached extraordinary prevalence in sp
282                     The protease NS3/4A from hepatitis C virus redistributes the complexes RIG-I/MAVS
283        Indeed, increased SALL4 expression in hepatitis C virus-related HCCs correlated with demethyla
284 further show that kinesin knockdown inhibits hepatitis-C virus replication in hepatocytes, likely bec
285 hepatitis before and after implementation of hepatitis C virus screening was assessed.
286 ssion, all from an active IVDU donor who was hepatitis C virus seronegative at time of donation, but
287 ceiving irrelevant T cells redirected toward hepatitis C virus-specific TCRs.
288 r End-Stage Liver Disease at transplant, and hepatitis C virus status.
289 ify the transmission dynamics that drive the hepatitis C virus subtypes 4a (HCV4a) and 4d (HCV4d) epi
290             There were 3 cases of unexpected hepatitis C virus transmission, all from an active IVDU
291 nce of some countries not following the 2016 hepatitis C virus treatment guidelines by the European A
292  rejection (n = 2 KT, 4 LT) occurred, during hepatitis C virus treatment in 4 and after cessation of
293                                    Extending hepatitis C virus treatment to patients in any fibrosis
294                                              Hepatitis C virus was the leading cause of hepatocellula
295             The Biochain ELISA kit for Human Hepatitis C Virus was used for antibody assay.
296  involved in the assembly and release of the hepatitis C virus, was determined from proteins expresse
297 the setting of viral hepatitis, particularly hepatitis C virus, where sustained viral response has be
298 ral direct-acting antiviral drugs (DAAs) for hepatitis C virus, which have response rates of 95% or m
299 ategy for patients chronically infected with hepatitis C virus who experience virologic failure after
300 dations on the care of patients with chronic hepatitis C virus who have achieved SVR.

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。
 
Page Top